CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 47 enrolled
Drug / intervention
Dutasteride +1 moredrug
Likely dose
Dutasteride 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01262287
NCT01262287Phase 4Completed

Placebo Controlled Pilot Study of Dutasteride for the Reduction of Alcohol Use in Male Drinkers

UConn Health·interventional·Posted Dec 17, 2010·Updated Mar 20, 2017

In Brief

A Phase 4 clinical trial evaluating Dutasteride and Placebo for Alcoholism and 2 related conditions. Completed, enrolled 47 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate whether dutasteride is safe and effective for reducing alcohol use in male drinkers who want to stop or reduce their drinking. The investigators hypothesize that at a dosage of 1mg/day, dutasteride will be well tolerated and that, compared to placebo treatment, dutasteride will result in a greater reduction in the amount of alcohol consumed per week. The study sample size is of a pilot scale and is designed to provide additional support for the study hypothesis and provide an estimate of likely effect sizes in order to design a more definitive study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 17, 2010
Enrollment StartJan 1, 2011
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 15.5 years ago

Interventions

Dutasteridedrug

dutasteride 4 mg loading dose followed by 1 mg daily for 8-week treatment period

Placebodrug

placebo capsules in same number as active drug, daily for 8-week treatment period